Masilukast - AstraZeneca/SAMA Pharmaceuticals
Alternative Names: D 3523; ICI D 3523; MCC-847; SA09012; ZD 3523Latest Information Update: 30 Jul 2019
At a glance
- Originator AstraZeneca
- Developer Mitsubishi Tanabe Pharma Corporation; SAMA Pharmaceuticals
- Class Antiasthmatics; Bronchodilators; Indoles
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
- Discontinued Allergic rhinitis
Most Recent Events
- 30 Jul 2019 Masilukast is still in clinical development for Asthma in South Korea (SAMA Pharmaceuticals pipeline, July 2019)
- 11 Sep 2015 Phase-II development for Asthma is ongoing in South Korea
- 15 Nov 2012 Masilukast licensed to SAMA Pharmaceuticals in South Korea